We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+17.28%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11B
AUM Growth
+$1.48B
Cap. Flow
-$1.03B
Cap. Flow %
-9.36%
Top 10 Hldgs %
83.4%
Holding
140
New
7
Increased
14
Reduced
16
Closed
6

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$55.6M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$44.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$40.8M
4
NGNE icon
Neurogene
NGNE
+$28.1M
5
EXEL icon
Exelixis
EXEL
+$25.4M

Top Sells

Rank Stock Value
1
XNPT
XENOPORT, INC.
XNPT
+$24.5M
2
MDVN
MEDIVATION, INC.
MDVN
+$19.9M
3
NVAX icon
Novavax
NVAX
+$17.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$16.2M
5
INSM icon
Insmed
INSM
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 82.76%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$2.38B 21.61%
44,100,294
+861,327
+2% +$40.8M
INCY icon
2
Incyte
INCY
$25.2B
$2.22B 20.11%
23,498,898
+201
+0% +$16.9K
ABBV icon
3
AbbVie
ABBV
$469B
$905M 8.21%
14,343,358
-30,180
-0.2% -$1.95M
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.46B
$821M 7.45%
25,819,768
+1,303,030
+5% +$44.2M
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$802M 7.28%
6,543,295
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.9B
$445M 4.04%
4,806,483
– –
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$398M 3.61%
13,770,302
+101,436
+0.7% +$2.83M
DBVT
8
DBV Technologies
DBVT
$799M
$200M 1.82%
550,956
– –
NGNE icon
9
Neurogene
NGNE
$648M
$141M 1.28%
526,805
+139,181
+36% +$28.1M
BLCM
10
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$96.8M 0.88%
486,565
– –
CERS icon
11
Cerus
CERS
$571M
$81.1M 0.74%
13,053,275
-500,000
-4% -$3.27M
ONCE
12
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$79.2M 0.72%
1,318,341
– –
ACOR
13
DELISTED
Acorda Therapeutics
ACOR
$76.4M 0.69%
30,509
– –
AMRN
14
Amarin Corp
AMRN
$300M
$65.8M 0.6%
1,031,524
+991,431
+2,473% +$55.6M
EXEL icon
15
Exelixis
EXEL
$14B
$63M 0.57%
4,929,494
+2,349,494
+91% +$25.4M
ONC
16
BeOne Medicines Ltd
ONC
$33.9B
$58.9M 0.53%
1,912,680
– –
NVTA
17
DELISTED
Invitae Corporation
NVTA
$57.4M 0.52%
6,554,967
– –
HRTX icon
18
Heron Therapeutics
HRTX
$92.5M
$49.2M 0.45%
2,857,250
– –
BCRX icon
19
BioCryst Pharmaceuticals
BCRX
$2.44B
$48.4M 0.44%
10,963,944
-4,046,590
-27% -$16.2M
NBIX icon
20
Neurocrine Biosciences
NBIX
$18.2B
$45.3M 0.41%
895,422
– –
AAAP
21
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$39.2M 0.36%
1,029,247
+196,158
+24% +$6.53M
ARAV
22
DELISTED
Aravive, Inc. Common Stock
ARAV
$26.1M 0.24%
355,708
-98,192
-22% -$7.1M
PGNX
23
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$23.1M 0.21%
3,650,808
-319,442
-8% -$1.93M
FOMX
24
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$22.8M 0.21%
2,466,702
+225,000
+10% +$1.88M
ARRY
25
DELISTED
Array Biopharma Inc
ARRY
$22.3M 0.2%
3,310,666
-1,000,000
-23% -$3.87M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2016 Portfolio in Review

As of Q3 2016, Baker Bros. Advisors held 140 positions worth $11B, up 16% from $9.54B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors withdrew a net $1.03B in Q3 2016, closing 6 positions and reducing 16 holdings. Its most notable exit was XENOPORT, INC., an estimated $24.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 81% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in ContraFect Corporation worth $10M.

  • Baker Bros. Advisors's largest Q3 2016 buy was ContraFect Corporation: 5,057 shares worth $10M.
  • Baker Bros. Advisors added most to Amarin Corp in Q3 2016, an estimated $55.6M increase.
  • Baker Bros. Advisors's biggest Q3 2016 reduction was BioCryst Pharmaceuticals, cutting an estimated $16.2M.
  • Baker Bros. Advisors fully exited XENOPORT, INC. in Q3 2016, selling an estimated $24.5M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $11B portfolio in Q3 2016.
  • Baker Bros. Advisors opened 7 new positions and closed 6 in Q3 2016.
  • Baker Bros. Advisors's portfolio value rose 16% quarter-over-quarter to $11B.

Based on Baker Bros. Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.